Q1 2019 Orion Oyj Earnings Call Transcript
(foreign language) Welcome to Orion's earnings call first quarter 2019. My name is Timo Lappalainen. We will hold first this session here. I have a few prepared remarks. Thereafter, we open the lines for any questions, comments that you may have. And at that time, I will also invite our CFO, Jari Karlson, here to the podium with me.
Firstly, I want to draw your attention to the disclaimer. This presentation contains forward-looking statements, which involve risks and uncertainty factors. And Orion assumes no obligation to update or revise any information included in this presentation.
Having said all that, let's first draw our attention to the highlights of the first quarter. Of course, the big event was that the marketing applications for darolutamide for our prostate cancer candidate molecule were -- that was submitted in the main markets, in the U.S. as well as in Europe and in Japan.
Our top line as well as the bottom line, those were lower than in comparable period. We continued
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
